Cancer · 2013 · 49 citations · 23 references
MedicineOncologyPathologyMetastasisMolecular OncologyNeuro-oncologyBrain MetastasesBrain MetastasisBrain TumorsMelanocytic TumorsMetastatic Brain TumorsNeuro-oncologic PathologyCancer Metastasis BiomarkersHistopathologic ExaminationImmune-related Gene SignaturesImmunohistochemical BiomarkersImmunohistochemical MarkersImmunohistochemical StainingImmunohistochemistry AssaysIntracranial Metastases
BACKGROUND: The prognosis of metastatic melanomas to the brain (MBM) is variable with prolonged survival in a subset. It is unclear whether MBM differ from extracranial metastases (EcM) and primary melanomas (PrM). METHODS: To study the biology of MBM, histopathologic analysis of tumor blocks from patients' craniotomy samples and whole-genome expression profiling (WGEP) with confirmatory immunohistochemistry were performed. RESULTS: High mononuclear infiltrate and low intratumoral hemorrhage were associated with prolonged overall survival (OS). Pathway analysis of WGEP data from 29 such craniotomy tumor blocks demonstrated that several immune-related BioCarta gene sets were associated with prolonged OS. WGEP analysis of MBM in comparison with same-patient EcM and PrM showed that MBM and EcM were similar, but both differ significantly from PrM. Immunohistochemical analysis revealed that peritumoral CD3⁺ and CD8⁺ cells were associated with prolonged OS. CONCLUSIONS: MBMs are more similar to EcM compared with PrM. Immune infiltrate is a favorable prognostic factor for MBM.
23
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin, Marc S. Ernstoff, Omid Hamid et al. · The Lancet Oncology · 2012 · 1.1K citations
Medicine, Oncology, Pharmacology +12
<i>NRAS</i> mutation status is an independent prognostic factor in metastatic melanoma
John Jakob, Roland L. Bassett, Chaan S. Ng et al. · Cancer · 2011 · 690 citations · Full text